Lung cancer trials in China

In China 1144 Also abroad 2746

1,144 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC
Where
Chongqing
Age
18 years and over
People
44
Run by
Xueqin Yang
See details and how to joinNCT06142058
Phase 2Not yet taking people in China
A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.
Where
Beijing
Age
18 years and over
People
37
Run by
Peking Union Medical College Hospital
See details and how to joinNCT06142617
Phase 1Taking people
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
Where
Wuhu
Age
18 years and over
People
60
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT06126406
No phaseNot yet taking people in China
Efficacy and Safety of BAI Combined With DEB-BACE of EqualSpheres in the Treatment of Advanced NSCLC
Where
Zhengzhou
Age
18 years and over
People
70
Run by
Gang Wu
See details and how to joinNCT06127329
Phase 2Taking people
Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC
Where
Jinan
Age
18 years to 75 years
People
51
Run by
Qianfoshan Hospital
See details and how to joinNCT06125041
Phase 3Not yet taking people in China
Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)
Where
Shanghai
Age
18 years to 80 years
People
286
Run by
Fudan University
See details and how to joinNCT06102161
No phaseTaking people
Exploring Cancer Evolution, Prognostic and Predictive Biomarkers in EGFR-mutant NSCLC
Where
Guanzhou
Age
18 years and over
People
150
Run by
Sun Yat-sen University
See details and how to joinNCT05997719
Phase 2Taking people
Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC
Where
Guangzhou
Age
18 years and over
People
126
Run by
Guangdong Association of Clinical Trials
See details and how to joinNCT06092086
Phase 3Taking people
SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations
Where
Shanghai
Age
18 years to 75 years
People
242
Run by
Nanjing Sanhome Pharmaceutical, Co., Ltd.
See details and how to joinNCT06080776
Phase 2Taking people
Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer
Where
Shijiazhuang
Age
18 years to 75 years
People
80
Run by
Hebei Medical University Fourth Hospital
See details and how to joinNCT05241028
Phase 1/2Taking people
Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression
Where
Guangzhou
Age
18 years and over
People
29
Run by
The First Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT05777278
No phaseTaking people
Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
Where
Tianjin
People
1,362
Run by
Tianjin Medical University Cancer Institute and Hospital
See details and how to joinNCT04631770
No phaseTaking people
Efficacy and Safety of Tislelizumab for Lung Adenocarcinoma With Asymptomatic Brain Metastatic
Where
Shijiazhuang
Age
18 years to 75 years
People
20
Run by
Hebei Medical University Fourth Hospital
See details and how to joinNCT06056115
Phase 3Taking people
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Where
Beijing, Nanjing, Shanghai
Age
18 years and over
People
570
Run by
Betta Pharmaceuticals Co., Ltd.
See details and how to joinNCT06041776
Phase 1Taking people
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
Where
Hangzhou
Age
18 years and over
People
30
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT06043466
Phase 3Taking people
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Where
Jinan
Age
18 years to 75 years
People
98
Run by
Qianfoshan Hospital
See details and how to joinNCT06043973
Phase 2Taking people
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
Where
Shanghai
Age
18 years to 75 years
People
100
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT04728724
Phase 3Taking people
Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)
Where
Shanghai
Age
18 years to 80 years
People
634
Run by
Fudan University
See details and how to joinNCT06031246
Phase 1Not yet taking people in China
Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation
Where
Bengbu, Changsha, Shanghai
Age
18 years to 75 years
People
172
Run by
Betta Pharmaceuticals Co., Ltd.
See details and how to joinNCT06015568
Phase 3Not yet taking people in China
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
Where
Baoding, Beijing, Bengbu, Binzhou, Changchun, Changsha, Changzhi, Chengdu, Chongqing, Fuzhou, Ganzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Hengshui, Jiamusi, Jinan, Kunming, Lanzhou, Luoyang, Mianyang, Nanchang, Nanyang, Qingdao, Qiqihar, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tangshan, Tianjin, Tonghua, Ürümqi, Weifang, Wuhan, Wuhu, Xi’an, Xining, Xinxiang, Xuzhou, Yibin, Yinchuan, Zhangzhou, Zhengzhou
Age
18 years and over
People
642
Run by
Akeso
See details and how to joinNCT05990127
Phase 2/3Taking people
Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT
Where
Guangzhou
Age
18 years and over
People
346
Run by
Sun Yat-sen University
See details and how to joinNCT05623267
No phaseTaking people
Comparison of Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
Where
Yangpu
Age
20 years to 79 years
People
446
Run by
Shanghai Pulmonary Hospital, Shanghai, China
See details and how to joinNCT05838053
No phaseTaking people
ELobectomy for NSCLC by VATS Versus Thoracotomy (ECTOP-1007)
Where
Shanghai
Age
18 years to 75 years
People
1,086
Run by
Fudan University
See details and how to joinNCT03786003
Phase 2Taking people
A Phase II Trial to Evaluate the Efficiency and Safety of Serplulimab Plus Chemotherapy as Conversion Therapy in NSCLC
Where
Hangzhou
Age
18 years to 75 years
People
49
Run by
Zhejiang University
See details and how to joinNCT05837052
Phase 1Not yet taking people in China
A Phase I Clinical Study of HS-20117 in Participants With Advanced Solid Tumors
Where
Tianjin
Age
18 years to 75 years
People
322
Run by
Hansoh BioMedical R&D Company
See details and how to joinNCT05940116